Cofoe Medical released its 2026 semi-annual report. First-half revenue reached 2.072 billion yuan, up 38.51 percent year on year, and net profit attributable to the parent company was 202 million yuan, up 20.84 percent. Among its businesses, respiratory support revenue came to 267 million yuan, up 166.90 percent, and second-quarter ventilator sales exceeded 100 million yuan, making it one of the fastest-growing core categories. The company plans an interim dividend of 6 yuan per 10 shares, totaling 136 million yuan. In addition, overseas revenue reached 210 million yuan, up 116.97 percent, and the company listed on the main board of the Hong Kong Stock Exchange on May 6, forming a dual A-share and H-share capital platform.
Cofoe Medical Technology Co.Ltd.H1 revenue and profit up strongly, with respiratory support revenue surging 166.9% and ventilator sales exceeding 100 million yuan in Q2, plus interim dividend and H-share listing.
